BACKGROUND AND PURPOSE: P2 receptors are involved in the regulation of ocular physiological processes like intraocular pressure (IOP). In the present study, the involvement of P2Y(2) receptors in the hypertensive effect of nucleotides was investigated by use of antagonists and of a siRNA designed for the P2Y(2) receptor. EXPERIMENTAL APPROACH: Agonists of the P2Y(2) receptor a as well as P2 antagonists were applied to eyes of New Zealand rabbits, and the changes in IOP were followed for up to 6 h. Cloning of the P2Y(2) receptor cDNA was done using a combination of degenerate reverse transcription PCR (RT-PCR) and rapid amplification of cDNA ends (RACE). siRNA was synthesized and tested by immunohistochemistry. KEY RESULTS: Single doses of 2-thioUTP, UTP-γ-S and UTP increased IOP. This behaviour was concentration-dependent and partially antagonized by reactive blue 2. Silencing the P2Y(2) receptor was observed in the ciliary body by immunohistochemistry labelling, where a reduction in the immunofluorescence was observed. This reduction in the expression of the P2Y(2) receptor was concomitant with a reduction in IOP, which was measurable 24 h after treatment with the siRNA, maximal after 2 days, followed by a slow increase towards control values for the following 5 days. Application of the P2Y(2) agonists after pretreatment of the animals with this siRNA did not produce any change in IOP. CONCLUSIONS AND IMPLICATIONS: P2Y(2) receptors increase IOP in New Zealand rabbits. The application of a siRNA for this receptor significantly reduced IOP, suggesting that this technology might be used for the treatment of glaucoma.
BACKGROUND AND PURPOSE: P2 receptors are involved in the regulation of ocular physiological processes like intraocular pressure (IOP). In the present study, the involvement of P2Y(2) receptors in the hypertensive effect of nucleotides was investigated by use of antagonists and of a siRNA designed for the P2Y(2) receptor. EXPERIMENTAL APPROACH: Agonists of the P2Y(2) receptor a as well as P2 antagonists were applied to eyes of New Zealand rabbits, and the changes in IOP were followed for up to 6 h. Cloning of the P2Y(2) receptor cDNA was done using a combination of degenerate reverse transcription PCR (RT-PCR) and rapid amplification of cDNA ends (RACE). siRNA was synthesized and tested by immunohistochemistry. KEY RESULTS: Single doses of 2-thioUTP, UTP-γ-S and UTP increased IOP. This behaviour was concentration-dependent and partially antagonized by reactive blue 2. Silencing the P2Y(2) receptor was observed in the ciliary body by immunohistochemistry labelling, where a reduction in the immunofluorescence was observed. This reduction in the expression of the P2Y(2) receptor was concomitant with a reduction in IOP, which was measurable 24 h after treatment with the siRNA, maximal after 2 days, followed by a slow increase towards control values for the following 5 days. Application of the P2Y(2) agonists after pretreatment of the animals with this siRNA did not produce any change in IOP. CONCLUSIONS AND IMPLICATIONS: P2Y(2) receptors increase IOP in New Zealand rabbits. The application of a siRNA for this receptor significantly reduced IOP, suggesting that this technology might be used for the treatment of glaucoma.
Authors: Hiroshi Nakamura; Shahid S Siddiqui; Xiang Shen; Asrar B Malik; Jose S Pulido; Nalin M Kumar; Beatrice Y J T Yue Journal: Mol Vis Date: 2004-10-04 Impact factor: 2.367
Authors: I D'Alimonte; R Ciccarelli; P Di Iorio; E Nargi; S Buccella; P Giuliani; M P Rathbone; S Jiang; F Caciagli; P Ballerini Journal: Int J Immunopathol Pharmacol Date: 2007 Apr-Jun Impact factor: 3.219
Authors: Andrew O Jo; Monika Lakk; Amber M Frye; Tam T T Phuong; Sarah N Redmon; Robin Roberts; Bruce A Berkowitz; Oleg Yarishkin; David Križaj Journal: Proc Natl Acad Sci U S A Date: 2016-03-22 Impact factor: 11.205
Authors: María J Pérez de Lara; Ana Guzmán-Aránguez; Pedro de la Villa; Juan Ignacio Díaz-Hernández; María Teresa Miras-Portugal; Jesús Pintor Journal: Mol Vis Date: 2015-09-02 Impact factor: 2.367
Authors: Begoña Fonseca; Alejandro Martínez-Águila; María J Pérez de Lara; Maria Teresa Miras-Portugal; Rosa Gómez-Villafuertes; Jesús Pintor Journal: Front Pharmacol Date: 2017-10-10 Impact factor: 5.810